Supplementary Material

Development of Highly Selective 1,2,3-Triazolecontaining Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors

Xue Zhi Zhao*, Kohei Tsuji, David Hymel, Terrence R. Burke, Jr.*

Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, U.S.A.

* Correspondence: xuezhi.zhao@nih.gov (X.Z.Z.) and burkete@nih.gov (T.R.B.Jr.); Tel.: +1-301-846-5907 (X.Z.Z.); +1-301-846-5906 (T.R.B.Jr.)

Inhibition of FP probe binding to isolated Plk1 PBD

to isolated Plk2 PBD Inhibition of FP probe binding to isolated

Inhibition of FP probe binding to isolated PIk3 PBD

Inhibition of FP probe binding to isolated PIk3 PBD

Inhibition of FP probe binding to isolated PIk3 PBD

2a
2b
3d
4b

Concentration (log M)

(b)

Inhibition of FP probe binding to isolated PIk3 PBD

Concentration (log M)

Concentration (log M)

Figure S1. Binding data obtained from FP assays using the PBDs of Plk1 (a), Plk2 (b) and Plk3 (c).

Experimental procedures are presented in the main text.

Inhibition of full length Plk1 by competitive ELISA




Figure S2. Binding data obtained from ELISA assays using full-length Plk1. Experimental procedures are presented in the main text.